Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintains a $33 price target.
July 30, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Day One Biopharmaceutical and maintained a $33 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $33 price target by a reputable analyst suggests a positive outlook for Day One Biopharmaceutical. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100